TL;DR
Researchers have engineered novel anti-CRISPR proteins (Acrs) with significantly enhanced potency and broader specificity than naturally occurring variants. By fusing domains to an existing Acr and employing structure-guided design, they created "designer Acrs" that offer more precise control over CRISPR-Cas systems, paving the way for safer and more versatile gene editing tools.
What Problem Does This Paper Address?
CRISPR-Cas systems have revolutionized molecular biology and medicine, enabling precise genome editing. However, the inherent activity of these systems can sometimes lead to unintended edits or off-target effects. Anti-CRISPR (Acr) proteins, naturally found in bacteriophages, act as inhibitors of CRISPR-Cas systems, providing a crucial "off-switch" to control their activity and improve precision. The challenge has been that naturally discovered Acrs are limited in their variety and may not effectively inhibit all Cas proteins of interest, especially those widely used in research and therapy like Staphylococcus aureus Cas9 (SauCas9). This paper addresses the need for more potent and broadly specific Acrs by developing a method to engineer them, moving beyond the limitations of naturally occurring sequences.
Methods
The study employed a two-pronged approach to engineer Acrs:
- Domain Insertion for Enhanced Potency: The researchers started with AcrIIC1, a known inhibitor of type II-C Cas9 systems. They hypothesized that inserting large, exogenous protein domains into a specific loop (loop 5) of AcrIIC1 could sterically hinder Cas9 activity and potentially interfere with DNA binding, thereby increasing inhibition. They created 11 different AcrIIC1 chimeras by fusing domains like mCherry and Avena sativa LOV2.
- Structure-Guided Design for Expanded Specificity: To broaden the specificity of Acrs, particularly to target the widely used Staphylococcus aureus Cas9 (SauCas9), the team used structural information. They generated a structural model of AcrIIC1 bound to the SauCas9 HNH domain and identified regions with suboptimal contacts. Using computational tools (RosettaScripts) for in silico mutagenesis, they designed mutations in AcrIIC1 to improve its binding affinity and inhibitory activity against SauCas9. This iterative process led to the creation of a triple mutant named AcrX.
Datasets
Not discussed in the paper. The study relies on existing structural data (PDB 4ZIN, 5VGB, 5F9R, 5CZZ) and experimental data generated by the authors.
Key Insights and Ideas
- Domain insertion is a powerful strategy to boost Acr potency: Simply adding a protein domain to an existing Acr can dramatically enhance its ability to inhibit Cas9, suggesting that steric hindrance plays a significant role.
- Structure-guided engineering can overcome natural Acr limitations: By understanding the structural basis of protein-protein interactions, researchers can rationally design Acrs with specificity for Cas proteins that lack natural inhibitors.
- Designer Acrs can achieve dual specificity: The engineered AcrX demonstrates the ability to inhibit both type II-C (like N. meningitidis Cas9) and type II-A (like S. aureus Cas9) CRISPR-Cas effectors, a feat not observed in natural Acrs. This broad applicability is a significant advancement.
- Acrs can be engineered for therapeutic applications: The development of potent and specific Acrs is crucial for advancing CRISPR-based gene therapies, offering a way to precisely control gene editing outcomes and minimize off-target effects.
Key Results
- Enhanced NmeCas9 Inhibition: AcrIIC1 chimeras, particularly AcrIIC1-mCherry chimera #10, showed over a 12-fold improvement in inhibiting N. meningitidis Cas9 (NmeCas9) compared to wild-type AcrIIC1. These engineered Acrs performed as well as or better than AcrIIC3, a previously known potent NmeCas9 inhibitor.
- Potent Inhibition at Low Acr:Cas9 Ratios: The chimeric inhibitors demonstrated strong Cas9 inhibition even at very low Acr:Cas9 vector ratios, indicating high efficiency.
- Creation of AcrX, a SauCas9 Inhibitor: Through structure-guided design, the researchers engineered AcrX, a triple mutant of AcrIIC1, which effectively blocked Staphylococcus aureus Cas9 (SauCas9) genome editing. AcrX achieved up to a ~30-fold improvement in inhibition compared to the parental AcrIIC1.
- Dual Specificity of AcrX: AcrX retained its inhibitory activity against NmeCas9 while gaining specificity for SauCas9, demonstrating a broader spectrum of inhibition.
- Effective Inhibition in Mammalian Cells: AcrX demonstrated potent SauCas9 inhibition in various mammalian cell lines (HEK 293T, U2OS, U87) and was effective even when delivered via AAV vectors, reducing indel formation to undetectable levels.
Limitations and Future Work
- Further Optimization: While AcrX shows promising dual specificity, further optimization might be possible to fine-tune its inhibitory profile for specific applications.
- In Vivo Efficacy: The study primarily focuses on cell-based assays. Future work would involve testing the in vivo efficacy and safety of these designer Acrs in relevant animal models.
- Broader Cas Protein Targets: The current work focuses on NmeCas9 and SauCas9. Expanding the engineering efforts to other Cas effectors used in gene editing would further broaden the utility of designer Acrs.
- Understanding Mechanisms: While the study suggests that domain insertion might interfere with DNA binding, a deeper mechanistic understanding of how these engineered Acrs function could lead to even more refined designs.
Summary updated